Surrogate markers in antiangiogenesis clinical trials

Novel antiangiogenic agents currently being developed may ultimately be more effective against solid tumours and less toxic than cytotoxic chemotherapy. As a result of the early clinical trials of angiogenesis inhibitors, investigators are beginning to appreciate the complexity of targeting angiogen...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Davis, D W, McConkey, D J, Abbruzzese, J L, Herbst, R S
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2003
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2394225/
https://ncbi.nlm.nih.gov/pubmed/12838293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601035
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller